Where Day One Biopharmaceutical Stands With Analysts
Portfolio Pulse from Benzinga Insights
Day One Biopharmaceutical (NASDAQ:DAWN) has received 5 bullish and 1 somewhat bullish ratings in the last quarter. The average 12-month price target from 6 analysts is $46.17, a 14.5% decrease from the previous average of $54.00.
August 08, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Day One Biopharmaceutical has received positive analyst ratings, but the average price target has decreased.
While the company has received positive ratings from analysts, the decrease in the average price target could indicate a potential decrease in the stock's value in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100